Merck & Co Inc

NYSE:MRK  
71.65
-0.32 (-0.44%)
5:28:11 PM EDT: $71.40 -0.25 (-0.35%)
Products, Strategic Combinations

HOOKIPA Collaborates With Merck To Evaluate HB-200 With Keytruda In Advanced Head And Neck Cancers

Published: 09/15/2021 11:10 GMT
Merck & Co Inc (MRK) - Hookipa Announces Collaboration With Merck, Kenilworth, Nj.
, USA to Evaluate Hb-200 With Keytruda in Patients With Advanced Head and Neck Cancers.
Hookipa Pharma Inc - Anticipates Initiating a Phase 2 Trial With Hb-200 in Combination With Keytruda in 2022.
Hookipa Pharma Inc - Additional Phase 2 Expansion Cohorts Are Also Planned to Start in Q1 2022.